drugset / Trial / NCT00578825

A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

NCT00578825

Unknown 340 enrolled Hospital Authority, Hong Kong
RandomizedParallel-groupDouble-blindTreatment

Summary

The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lopinavir Other / unclassified
Subject Ribavirin Small molecule
Subject Ritonavir Other / unclassified